This was owing to the sensitivity to LDHA inhibition in pancreatic cancer depending on the status of TP53, with TP53 wild-type patients showing complete resistance to FX11 and TP53 mutant patients showing a therapeutic response47. Here, TP53 is linked to pancreatic neoplasm.